The SARS-CoV-2 Toolbox: Innovative Initiatives to Support the Development of Vaccines & Therapeutics, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, attendees will learn from vaccine and infectious disease experts about the preclinical and clinical techniques and technologies being deployed to help speed up the development of vaccines and therapeutics for the SARS-CoV-2 virus. The featured speakers will discuss the various initiatives the Nexelis group is leading to support global research efforts in the field.

Xtalks Life Science Webinars

Nexelis brings together global expertise in immunology, infectious diseases and vaccines to speed up development programs from the earliest stages of design and candidate optimization, to preclinical studies and clinical trials.

Join Luc Gagnon, VP Vaccine Sciences, Nexelis, Sofie Pattijn, Co-Founder & Chief Technology Officer, ImmunXperts, Danielle Poirier, Director Preclinical Research, Nexelis and Bassam Hallis, Head of Preclinical Development, Public Health England in a live webinar on Monday, April 20, 2020 at 11am EDT (4pm BST/UK).

The WHO identified that immune correlates will be a necessary evaluation criterion. A standardized set of assays will provide regulatory agencies with datasets that can be compared across the different modalities.

Working with one organization equipped to run immunogenicity projects from lead screening to Phase III trials provides development teams with significant advantages including timeline efficiencies and knowledge preservation at stage transitions.

Nexelis brings together global expertise in immunology, infectious diseases and vaccines to speed up development programs from the earliest stages of design and candidate optimization, to preclinical studies and clinical trials. Through internal R&D capabilities and external collaborations, innovative tools and technologies are being developed to further advance the field. For example, currently in development is an exhaustive panel of immunoassays that will help reduce vaccine development time by a minimum of three months.

Through a strategic partnership with Public Health England (PHE-Porton), a renowned centre of excellence for infectious diseases, Nexelis leverages unique expertise in high containment microbiology and extensive experience in the development and application of GXP pre-clinical models for the evaluation of pathogenesis and efficacy/potency of vaccines and therapeutics.

For more information or to register for this event, visit The SARS-CoV-2 Toolbox: Innovative Initiatives to Support the Development of Vaccines & Therapeutics.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website